Literature DB >> 304590

Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time.

G Mathé, O Halle-Pannenko, C Bourut.   

Abstract

Cyclophosphamide (CPM) chemotherapy (134 mg/kg) of L1210 leukemia is less efficient in mice previously immunodepressed by antithymocyte serum (ATS) than in non-ATS pretreated mice. On the other hand, administration of a higher dose of CPM (403 mg/kg), which kills a greater number of leukemic cells but induces an immunodepression, according to the skin graft test, results in a shorter survival time than does the administration of a lower dose of CPM (134 mg/kg), capable of killing fewer leukemic cells but not inducing such an immunodepression. Thus, it appears that: (1) the antileukemic effect of the same dose of a chemotherapeutic drug is less efficient in immunodepressed than in nonimmunodepressed hosts, and (2) calculation of the number of neoplastic cells killed by a given chemotherapy by extrapolation from the survival time may lead to erroneous conclusions.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 304590     DOI: 10.1007/978-3-642-81174-6_3

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  16 in total

1.  Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice.

Authors:  M Hayat; C Bourut; E Chenu; J L Montero; J L Imbach; J S MacDonald; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally?

Authors:  G Mathé; C Jasmin
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Chemotherapy, a double agent in respect of immune functions.

Authors:  G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

4.  Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

Authors:  L M Weiskirch; Y Bar-Dagan; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

5.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.

Authors:  E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors:  L M Weiskirch; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge.

Authors:  D Vidović; M Marusić; F Culo
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

9.  Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.

Authors:  M M Bartik; M C Ahn; B A Baumgartel; R L Hendricks; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Cytocidal and toxic effect of various cytostatic drugs on three ascites tumors of the mouse.

Authors:  E Schäfer; B Maurer-Schultze
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.